Market Place
Sourcing Support
Avidity Bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
20 Dec 2024 //
PR NEWSWIRE
Avidity Announces New Precision Cardiology Development Candidates
12 Nov 2024 //
PR NEWSWIRE
Avidity Biosciences Reports Q3 2024 Financials & Highlights
07 Nov 2024 //
PR NEWSWIRE
Avidity Bio to Host Investor Event on Precision Cardiology Nov 12
31 Oct 2024 //
PR NEWSWIRE
Avidity Accelerate Approval in Fortitude Facioscapulohumeral MD
30 Oct 2024 //
PR NEWSWIRE
Avidity Announce FDA Lifts Partial Hold On Del-desiran Program
03 Oct 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Inducement Grants
23 Sep 2024 //
PR NEWSWIRE
Avidity Raises Awareness for National Muscular Dystrophy Awareness Month
05 Sep 2024 //
PR NEWSWIRE
Life Science Cares San Diego Expands Partnership With Avidity Biosciences
27 Aug 2024 //
BUSINESSWIRE
Avidity Biosciences Announces Inducement Grants
21 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences Closes Upsized Public Offering With Full Option
19 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Proposed Public Offering of Common Stock
13 Aug 2024 //
PR NEWSWIRE
Analysts dig into details of Avidity`s DMD win, revealing nuances in strong data
12 Aug 2024 //
FIERCE BIOTECH
Avidity`s AOC 1044 Shows Positive Data In Duchenne Muscular Dystrophy Trial
09 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences Reports Q2 2024 Results And Recent Highlights
09 Aug 2024 //
PR NEWSWIRE
Avidity Appoints John B. Moriarty, Jr. As Chief Legal Officer
05 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Inducement Grants
05 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Inducement Grants Under Nasdaq Rule
22 Jul 2024 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Jun 2024 //
PR NEWSWIRE
Avidity Biosciences Partners With FSHD Society For World FSHD Day Awareness
20 Jun 2024 //
PR NEWSWIRE
Avidity Biosciences Closes Upsized Public Offering Of Common Stock
17 Jun 2024 //
PR NEWSWIRE
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
13 Jun 2024 //
PR NEWSWIRE
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
12 Jun 2024 //
PR NEWSWIRE
Avidity therapy shows possible benefit in muscular dystrophy
12 Jun 2024 //
FIERCE BIOTECH
Avidity Presents Prelim FORTITUDE Data On AOC 1020 In FSHD
29 May 2024 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq Rule
21 May 2024 //
PR NEWSWIRE
Avidity Biosciences Appoints Simona Skerjanec To Board Of Directors
15 May 2024 //
PR NEWSWIRE
Avidity Biosciences Q1 2024 Financials, Highlights
09 May 2024 //
PR NEWSWIRE
Avidity Gets FDA Breakthrough Status For Dystrophy Drug
08 May 2024 //
PR NEWSWIRE
Avidity Bio Announces Nasdaq Inducement Grants
22 Apr 2024 //
PR NEWSWIRE
Avidity Biosciences to Participate in Upcoming Investor Conferences
27 Mar 2024 //
PRESS RELEASE
Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Mar 2024 //
PR NEWSWIRE
Avidity accelerates DM1 Phase III trial on the heels of further positive data
04 Mar 2024 //
PRESS RELEASE
Avidity Biosciences Announces Positive AOC 1001 Long-term Data
04 Mar 2024 //
PR NEWSWIRE
Avidity Biosciences Honors Rare Disease Day®
29 Feb 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
29 Feb 2024 //
PRESS RELEASE
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044
20 Feb 2024 //
PR NEWSWIRE
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data
15 Feb 2024 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Jan 2024 //
PR NEWSWIRE
Avidity Bio Announces 2024 Corporate Priorities
05 Jan 2024 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Dec 2023 //
PR NEWSWIRE
BMS Expands Cardio Partnership with Avidity in Potential $2.3B Deal
29 Nov 2023 //
BIOSPACE
Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Nov 2023 //
PR NEWSWIRE
Avidity Biosciences Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 Oct 2023 //
PR NEWSWIRE
Avidity Announces AOC 1001 Data Showing Improvement in Functional Endpoints
07 Oct 2023 //
PR NEWSWIRE
Avidity Biosciences Announces Upcoming Presentations at Muscle Society
26 Sep 2023 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Sep 2023 //
PR NEWSWIRE
Avidity Biosciences Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing
21 Jun 2023 //
PR NEWSWIRE
Avidity Biosciences Joins with Patients, Caregivers & Healthcare Globally
20 Jun 2023 //
PR NEWSWIRE
Avidity Biosciences Announces Presentations at 30th Annual FSHD Society Congress
08 Jun 2023 //
PR NEWSWIRE
Avidity says FDA has `eased` partial hold on lead asset
18 May 2023 //
FIERCE BIOTECH
Avidity Biosciences Reports1Q 2023 FYR and Recent Highlights
09 May 2023 //
PR NEWSWIRE
Avidity Biosciences Announces Positive Topline Data from AOC 1001 Ph1/2 MARINA™
27 Apr 2023 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Apr 2023 //
PR NEWSWIRE
Avidity to Host Event Focused on AOC 1001 Data from Phase 1/2 MARINA Trial
13 Apr 2023 //
PR NEWSWIRE
Avidity Biosciences Provides Regulatory Update on AOC 1001
30 Mar 2023 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Mar 2023 //
PR NEWSWIRE
Avidity Biosciences to Participate in Upcoming Investor Conference
01 Mar 2023 //
PR NEWSWIRE
